Skip to main content

Table 1 Characteristics of all patients classified as having nonradiographic axial spondyloarthritis at inclusion in SCQM

From: Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort

Parameter

A. All nr-axSpA patients

B. All nr-axSpA patients excluding patients with co-morbid FM

N, 495

Men, N = 231

Women, N = 264

p

N, 470

Men, N = 227

Women, N = 243

p

Age, years

495

36.6 (10.9)

38.2 (10.7)

0.09

470

36.4 (10.9)

38.1 (10.7)

0.09

Age at symptom onset, years

481

28.3 (8.4)

28.7 (9.1)

0.65

456

28.2 (8.4)

28.6 (9.0)

0.65

Symptom duration, years

481

8.3 (9.2)

9.6 (9.8)

0.10

456

8.2 (9.2)

9.5 (9.8)

0.12

Diagnostic delay, years

480

4.7 (7.6)

6.0 (7.8)

0.005

455

4.7 (7.5)

6.0 (7.8)

0.01

HLA-B27 positive, %

453

76.5

67.0

0.03

430

77.0

68.2

0.05

Positive family history for spondyloarthritis, %

417

32.0

40.5

0.08

393

32.1

42.0

0.05

Prior sacroiliitis on MRI, %

477

52.9

58.7

0.23

453

53.9

58.5

0.34

BASDAI

430

4.6 (2.2)

5.3 (2.1)

0.003

412

4.6 (2.2)

5.1 (2.1)

0.02

• BASDAI 1 (fatigue)

436

4.7 (2.8)

6.0 (2.4)

< 0.001

418

4.7 (2.8)

5.9 (2.4)

< 0.001

• BASDAI 2 (back pain)

436

5.9 (2.7)

6.5 (2.5)

0.03

418

5.9 (2.7)

6.3 (2.5)

0.10

• BASDAI 3 (joint pain/swelling)

435

3.6 (3.1)

4.2 (3.1)

0.04

417

3.6 (3.1)

4.1 (3.1)

0.07

• BASDAI 4 (enthesitis)

433

4.2 (3.3)

5.0 (3.1)

0.02

415

4.2 (3.3)

4.8 (3.0)

0.04

• BASDAI 5 (intensity of morning stiffness)

434

5.2 (3.0)

5.4 (3.1)

0.65

416

5.3 (3.0)

5.2 (3.1)

0.96

• BASDAI 6 (duration of morning stiffness)

433

4.0 (2.9)

4.1 (2.9)

0.68

415

4.0 (2.9)

4.0 (2.9)

0.99

Physician Global Assessment

481

3.7 (2.2)

3.8 (2.0)

0.49

412

3.7 (2.2)

3.7 (2.0)

0.86

Patient Global Assessment

430

5.3 (2.9)

5.6 (2.8)

0.27

412

5.3 (2.9)

5.5 (2.8)

0.54

ASDAS

402

2.9 (1.0)

2.9 (0.9)

0.23

386

2.9 (1.0)

2.9 (0.9)

0.49

CRP (mg/l), median (IQR)

463

4.0 (1.0; 8.0)

4.0 (2.0; 8.0)

0.86

441

4.0 (1.1; 8.0)

4.0 (2.0; 8.0)

0.96

Elevated CRP, %

459

26.5

26.6

1.00

437

26.5

26.1

1.00

BASFI

435

2.8 (2.4)

3.1 (2.5)

0.16

416

2.8 (2.4)

2.9 (2.4)

0.54

BASMI

473

1.3 (1.4)

1.3 (1.3)

0.98

449

1.4 (1.4)

1.3 (1.2)

0.72

EQ-5D

431

61.4 (22.5)

59.7 (20.1)

0.34

412

61.3 (22.6)

61.2 (19.4)

0.78

IBP according to ASAS, %

462

80.5

77.3

0.43

437

80.6

77.0

0.41

Spinal MRI inflammation, %

476

26.9

24.9

0.67

452

26.9

23.6

0.45

Spinal radiographic changes, %

476

6.3

3.6

0.20

452

5.9

3.0

0.17

Current peripheral arthritis,%

489

35.8

39.2

0.46

464

36.0

38.9

0.57

Number of swollen joints

481

0.7 (1.9)

0.9 (2.3)

0.38

457

0.7 (1.9)

0.7 (1.8)

0.54

Current enthesitis, %

483

64.0

79.6

< 0.001

459

63.8

78.3

< 0.001

Modified MASES

481

1.9 (2.5)

3.2 (3.4)

< 0.001

457

1.8 (2.5)

2.9 (3.1)

< 0.001

Co-morbid fibromyalgia, %

307

2.7

13.1

< 0.001

Dactylitis ever, %

492

10.9

11.4

0.89

468

10.6

12.0

0.66

Uveitis ever, %

434

18.1

13.1

0.18

410

18.4

12.9

0.14

Psoriasis ever, %

373

9.1

9.1

1.00

351

9.3

8.4

0.85

Inflammatory bowel disease ever, %

427

6.0

7.9

0.46

403

5.6

8.2

0.33

Taking NSAIDs, %

471

87.3

90.4

0.31

447

87.6

89.6

0.55

Taking methotrexate, %

495

5.2

10.2

0.04

470

5.3

9.9

0.08

Taking sulfasalazine, %

495

4.8

6.1

0.56

470

4.8

6.2

0.55

Taking TNFi, %

495

14.7

15.5

0.90

470

14.5

15.2

0.90

Ever TNFi, %

495

68.0

72.0

0.78

470

67.4

70.8

0.80

Current smoking, %

432

32.0

30.2

0.75

413

32.0

28.3

0.45

Body mass index

483

25.7 (3.9)

24.3 (4.5)

< 0.001

458

25.6 (3.9)

24.1 (4.2)

< 0.001

Education, %

462

  

0.46

440

  

0.52

• Compulsory

 

15.8

19.8

  

15.2

18.3

 

• Vocational

 

56.7

51.8

  

57.4

52.4

 

• University

 

27.4

28.3

  

27.5

29.3

 

Absenteeism within last year, %

389

53.9

44.0

0.12

372

53.9

43.2

0.10

  1. All patients with nr-axSpA are presented in A, while patients with co-morbid fibromyalgia are excluded in B. Except where indicated otherwise, values are the mean (SD). Data in bold are statistically significant. ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, EQ-5D EuroQol 5-domains, FM fibromyalgia, HLA-B27 human leucocyte antigen B27, IBP inflammatory back pain, MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the plantar fascia in the count, MRI magnetic resonance imaging, nr-axSpA nonradiographic axial spondyloarthritis, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor necrosis factor inhibitor